Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BActinium-1: [225Ac]Ac-AKY-2519 in Metastatic Castration-Resistant Prostate Cancer
NCT07581184Phase 1Recruiting
- Sponsor
- Aktis Oncology
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of AKY-2519 in castration-resistant prostate cancer (CRPC) (2 cohorts), sponsored by Aktis Oncology. Primary endpoints: Occurrence of adverse events by severity and occurrence of serious adverse events (SAEs) in participants who received [225Ac]Ac-AKY-2519 at 30 days and Occurrence of dose-limiting toxicity (DLT) at 28 days. Started Jun 2026; status: recruiting.
02
Drugs
AKY-2519
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07581184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581184.